Company profile
Aeovian Pharmaceuticals, Inc.
Privately held: no public share price (Bay Area clinical-stage biotech developing selective mTORC1 inhibitors (lead: AV078) for Tuberous Sclerosis Complex-related epilepsy; privately held, raised a $37M Series A (2019) and a $55M Series B (Dec 2025). No public listing. Sources: https://clinicaltrials.gov/study/NCT07680322 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://www.businesswire.com/news/home/20251216261885/en/Aeovian-Pharmaceuticals-Raises-$55-Million-to-Advance-First-in-Class-Selective-mTORC1-Inhibitor-for-Tuberous-Sclerosis-Complex-Related-Epilepsy Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | mTORC1 (mammalian target of rapamycin complex 1) (inhibitor)Small molecule | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.